Proclara Biosciences Garners $47,000,000 Series E Financing

  • Feed Type
  • Date
  • Company Name
    Proclara Biosciences
  • Mailing Address
    222 3rd St. Cambridge, MA 02142 USA
  • Company Description
    Proclara Biosciences is a biotechnology company advancing product candidates developed based on proprietary GAIM technology, which is capable of simultaneously targeting multiple toxic misfolded proteins.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series E
  • Proceeds Purposes
    The financing will support further clinical development of NPT088, as well as the preclinical advancement of additional molecules toward the clinic. With completion of this financing, Proclara has raised more than $110 million to date.
  • M&A Terms
  • Venture Investor
    Merieux Developpement
  • Venture Investor

Trending on Xconomy